Lenox Hill Hospital, New York
Diffuse alveolar hemorrhage reported after infliximab therapy
Published in Healthcare Finance, Tax and Law Weekly, June 30th, 2004
According to recent research from the United States, "[i]nfliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor-alpha (anti-TNF-alpha), is being used with increasing frequency in the treatment of Crohn disease."
"Infliximab's safety profile to date has been good with reported adverse events being mild to moderate," noted S. Panagi and coauthors at Lenox Hill Hospital in New York City. However, the collaborators described "a case of diffuse alveolar hemorrhage after the second infliximab infusion in a patient with Crohn disease."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- ARYx Therapeutics Inc.
Pharmaceutical R&D company completes $55M Series D financing - ARYx Therapeutics, Inc.
Drug discovery firm completes series D financing - Acquired and Inherited Diseases
Targeted Genetics signs exclusive license agreement with NIH - Advanced Medical Optics, Inc.
Ophthalmology company increases stockholders' equity through debt reduction - Advanced Neuromodulation Systems
Pain therapy device firm announces stock repurchase plan - Alexion Pharmaceuticals, Inc.
Pharmaceutical company reports loss of $0.69 per share - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
